T. Dong

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

Panteleimon G. Takis, Jordan J. Clark, Michael J. Murphy, 2022, eBioMedicine.